CNCE
Concert Pharmaceuticals, Inc.
CNCE
CNCE
Delisted
CNCE was delisted on the 3rd of March, 2023.
120 hedge funds and large institutions have $290M invested in Concert Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 53 increasing their positions, 26 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
120
Holders Change
-3
Holders Change %
-2.44%
% of All Funds
2.75%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
21
Increased
53
Reduced
26
Closed
24
Calls
$462K
Puts
$462K
Net Calls
–
Net Calls Change
-$881K
Top Buyers
| 1 |
Millennium Management
New York
|
+$3.83M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.46M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$2.08M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.93M |
| 5 |
Renaissance Technologies
New York
|
+$1.89M |
Top Sellers
| 1 |
GTC
Ghost Tree Capital
New York
|
-$8.02M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$4.06M |
| 3 |
SAM
Senzar Asset Management
New York
|
-$2.85M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$2.63M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$2M |
